Besifloxacin Brand Name– Besivance
What is Besifloxacin
Besifloxacin is a fluoroquinolone ophthalmic suspension indicated for the treatment of bacterial conjunctivitis.
Besifloxacin was approved by the FDA in April 2009.
Indications
- Aerococcus viridans
- bacterial conjunctivitis
- CDC coryneform group G
- Corynebacterium pseudodiphtheriticum
- Corynebacterium striatum
- Haemophilus influenzae (beta-lactamase negative)
- Haemophilus influenzae (beta-lactamase positive)
- Moraxella catarrhalis
- Moraxella lacunata
- Pseudomonas aeruginosa
- Staphylococcus aureus (MSSA)
- Staphylococcus epidermidis
- Staphylococcus hominis
- Staphylococcus lugdunesis
- Staphylococcus warneri
- Streptococcus mitis
- Streptococcus oralis
- Streptococcus pneumoniae
- Streptococcus salivarius
Side Effects
- blurred vision
- conjunctival hyperemia
- headache
- ocular irritation
- ocular pain
- ocular pruritus
- superinfection
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- contact lenses
- fungal infection
- geriatric
- infants
- infection
- neonates
- pregnancy
- quinolone hypersensitivity
Interactions
There are no drug interactions associated with Besifloxacin products.